What is the Neuroimmunology Market Size?
The global neuroimmunology market was calculated at USD 37.80 billion in 2025 and is estimated to grow from USD 41.15 billion in 2026 to USD 91.88 billion by 2035, registering a CAGR of 8.90% during the forecast period from 2026 to 2035.

Key Takeaways
- North America dominated the global neuroimmunology market with a share of 39% in 2025.
- Asia-Pacific is expected to grow at the fastest CAGR of 13.5% during the forecast period.
- By disease type, the multiple sclerosis segment led the global market with a share of 36% in 2025.
- By disease type, the neuroinflammatory disorders segment held 9% of the market share in 2025 and is expected to grow at the fastest CAGR of 12.5% between 2026 and 2035.
- By treatment type, the monoclonal antibodies segment accounted for a revenue share of 30% in the market in 2025.
- By treatment type, the cell-based therapies segment is expected to grow at the highest CAGR of 18.5% between 2026 and 2035.
Neuroimmunology Market Overview
The neuroimmunology market encompasses the global pharmaceutical, biotechnology, and diagnostic industries focused on understanding, diagnosing, and treating disorders caused by interactions between the nervous and immune systems. The market primarily includes therapies and diagnostic solutions for neuroinflammatory and autoimmune neurological conditions. Growth is largely driven by the increasing prevalence of neurological and autoimmune diseases worldwide, including conditions such as Multiple Sclerosis, Alzheimer’s Disease, and Autoimmune Encephalitis, which continue to increase the demand for advanced treatment and diagnostic options.
How is AI Influencing the Neuroimmunology Market?
Artificial intelligence (AI) is transforming the neuroimmunology market by accelerating drug discovery, improving diagnostic accuracy, and enabling personalized treatment approaches. By analyzing complex neuroimmune interactions, AI helps researchers and clinicians better understand and manage challenging neurological disorders. Advanced AI algorithms integrate data from electronic health records (EHRs), longitudinal patient studies, and multi-omics datasets to identify disease patterns, predict progression, and support clinical decision-making. These capabilities allow healthcare providers to model various treatment scenarios and forecast individual patient outcomes, ultimately enhancing the precision and effectiveness of neuroimmunology therapies.
Neuroimmunology Market Regional Analysis
North America Neuroimmunology Market Size and Growth 2026 to 2035
The North America neuroimmunology market was valued at USD 14.74 billion in 2025 and is expected to reach approximately USD 30.00 billion by 2035, expanding at a CAGR of 7.80% during the forecast period from 2026 to 2035.

Which Factors Supported North America’s Dominance in the Neuroimmunology Market?
North America dominated the market with a major share of 39% in 2025. This dominance is supported by the high prevalence of neuroimmune and autoimmune neurological disorders and the strong acceptance of biologics and monoclonal antibody therapies. Innovations in biomarker detection, the integration of AI-enabled neuroimaging, and next-generation sequencing enable earlier and more accurate diagnoses.
How is Europe Growing in the Neuroimmunology Market?
Europe held the second-largest market share of 30% in 2025 and is expected to grow at a notable CAGR of 7.5% during the projection period, driven primarily by strong public healthcare systems supporting neuroimmune treatments and increasing focus on precision neurology and biologics. Progress in biologicals and small-molecule drug discovery, coupled with the expanded usage of biologics and targeted therapies, has revolutionized patient care pathways.
UK Market Analysis
The UK market is mainly driven by an aging population, the rising prevalence of autoimmune and neurological conditions, and heavy investments in neurological drug and biomarker research. A robust healthcare infrastructure and strategic government backing have further accelerated expansion in this specialized medical sector.
Will Asia-Pacific Grow in the Neuroimmunology Market?
Asia-Pacific held a 22% share of the market in 2025 and is expected to grow at the fastest CAGR of 13.5% during the projection period, driven by the rapidly expanding healthcare infrastructure in China and India, increasing awareness, and diagnosis of neuroimmune disorders. Increased patient knowledge regarding neurological health and the push for early disease detection have directly led to higher diagnostic testing rates along with clinical trial activities across the region.
Market Report Coverage and Key Metrics
| Report Coverage | Details |
| Market Size in 2025 | USD 37.80 Billion |
| Market Size in 2026 | USD 41.15 Billion |
| Market Size by 2035 | USD 91.88 Billion |
| Market Growth Rate from 2026 to 2035 | CAGR of 8.90% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
Neuroimmunology Market Leading Companies
- Biogen Inc. is a leading biotechnology company specializing in therapies for neurological and neuroimmunological disorders, with a strong portfolio in multiple sclerosis (MS) treatments. The company continues to invest in innovative research for neurodegenerative and autoimmune diseases.
- F. Hoffmann-La Roche Ltd is a global healthcare leader focused on pharmaceuticals and diagnostics, developing advanced therapies for neurological and immune-mediated disorders. Its precision medicine approach supports personalized neuroimmunology treatments.
- Novartis AG develops innovative medicines for a wide range of diseases, including neuroimmunological conditions such as multiple sclerosis. The company emphasizes advanced biologics and gene-based therapies.
- Sanofi S.A. is a major global pharmaceutical company with expertise in immunology and rare diseases. It actively invests in research aimed at improving outcomes for patients with neurological and autoimmune disorders.
- Bristol Myers Squibb focuses on developing therapies across immunology, oncology, and neuroscience. The company leverages advanced research platforms to address immune-mediated neurological diseases.
- Merck KGaA has a strong presence in neuroimmunology through its multiple sclerosis treatment portfolio and ongoing research initiatives. The company also supports innovation in precision healthcare and biotechnology.
- Alexion Pharmaceuticals specializes in developing therapies for rare and severe immune-mediated disorders, including neurological conditions. Its expertise in complement biology has strengthened its position in neuroimmunology.
- AbbVie Inc. develops innovative treatments across immunology, neuroscience, and other therapeutic areas. The company continues to expand its neuroimmunology research pipeline through strategic investments and collaborations.
Check this report to: Immunochemistry Instruments and Reagents Market
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview: https://www.precedenceresearch.com/sample/8446
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344